Results from a phase II trial show that the BRAF inhibitor dabrafenib has significant single-agent activity in patients with advanced non–small cell lung cancer harboring the BRAF V600E mutation. However, data from another arm of the study suggest that combining dabrafenib with a MEK inhibitor may be a more effective treatment strategy for these patients.
from Cancer via ola Kala on Inoreader http://ift.tt/296vv4h
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου